These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38064144)

  • 1. Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.
    Woo H; Shin G; Lee D; Kwon HY; Bae S
    BioDrugs; 2024 Jan; 38(1):133-144. PubMed ID: 38064144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.
    Peng K; Blais JE; Pratt NL; Guo JJ; Hillen JB; Stanford T; Ward M; Lai EC; Shin JY; Tong X; Fan M; Cheng FWT; Wu J; Yeung WWY; Lau CS; Leung WK; Wong ICK; Li X
    BioDrugs; 2023 May; 37(3):409-420. PubMed ID: 36952213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to biologicals in Crohn's disease in ten European countries.
    Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
    World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
    Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
    [No Abstract]   [Full Text] [Related]  

  • 7. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 8. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
    Berreur B; Guerin F; Christophe B; Limido G; Paubel P
    Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
    Anderson E; Waller K; Tamilarasan AG; Lin H; Paramsothy S; Leong RW
    Expert Opin Biol Ther; 2023; 23(8):819-825. PubMed ID: 37070385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI; Fitzpatrick RW; Chapman SR
    Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
    Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
    Front Public Health; 2021; 9():671961. PubMed ID: 34249838
    [No Abstract]   [Full Text] [Related]  

  • 19. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.